Literature DB >> 3941762

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators.

E Melamed, V Bitton, O Zelig.   

Abstract

Episodic total unresponsiveness to single doses of L-dopa developed in 14 of 32 parkinsonians with declining efficacy and response fluctuations after chronic L-dopa therapy. Complete lack of clinical benefit after occasional doses was unpredictable, occurred at least once daily mostly in the afternoon, and differed from other response failures related to food intake. In two patients, total unresponsiveness after dose ingestion coincided with lack of increases in plasma L-dopa levels suggesting that phenomenon was due, in part, to failure of L-dopa absorption from the gut.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3941762     DOI: 10.1212/wnl.36.1.100

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  DBS candidates that fall short on a levodopa challenge test: alternative and important indications.

Authors:  Takashi Morishita; Maryam Rahman; Kelly D Foote; Kyle M Fargen; Charles E Jacobson; Hubert H Fernandez; Ramon L Rodriguez; Irene A Malaty; Dawn Bowers; Christopher J Hass; Yoichi Katayama; Takamitsu Yamamoto; Michael S Okun
Journal:  Neurologist       Date:  2011-09       Impact factor: 1.398

5.  What's in a name? The classification of common headaches.

Authors:  S J Ellis
Journal:  Postgrad Med J       Date:  1997-04       Impact factor: 2.401

Review 6.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 7.  Parkinson's disease.

Authors:  C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

Review 8.  Drug treatment of Parkinson's disease in the 1990s. Achievements and future possibilities.

Authors:  A J Hughes
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 9.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

Review 10.  Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects.

Authors:  Chethan Ramprasad; Jane Yellowlees Douglas; Baharak Moshiree
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.